Home /
EMA recommends withdrawal of Tavneos (avacopan) marketing authorization The European Medicines Agency proposes withdrawing Tavneos , a vasculitis treatment.
Published 8sem · 1 source Notable · updated 1sem
The fact This drug, used for granulomatosis with polyangiitis, no longer shows sufficient benefit.
Affected patients will need gradual withdrawal under medical supervision.
🔗 Click the link to read an article on the topic:
Why it matters Cette décision pourrait affecter des milliers de patients en Europe traités pour une maladie rare et grave, nécessitant une transition thérapeutique encadrée.
What if you saw the whole news differently? Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page. → Auto-synthesis from 1 media source · identified on July 17, 2026